Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
Track: The Visual Abstract
Can rivaroxaban reduce cardiovascular events in advanced CKD?
The TRACK trial compared low-dose rivaroxaban with placebo in patients with stage 4–5 CKD and dialysis-dependent kidney failure at high cardiovascular risk.
Check out the latest VA and review the next #NephJC.
Track: El Resumen Visual
¿Puede rivaroxabán reducir los eventos cardiovasculares en la ERC avanzada?
El estudio TRACK comparó rivaroxabán a dosis bajas frente a placebo en pacientes con ERC estadio 4–5 y enfermedad renal en diálisis con alto riesgo cardiovascular.
Revisa nuestro más reciente resumen visual y acompáñanos en la próxima discusión de #NephJC.
NephJC Short: The map and the territory: what measured GFR teaches us about our estimates
Dialyze Less, Recover More? AKI’s Chance to Get LIBERATE-D
Dialysis deferred, logic recycled: BICAR ICU2
NephJC Shorts: zilebesiran silencing hypertension via RNA interference
NephJC Shorts: Salt reduction still lowers BP
NephJC Shorts: BedMed and Chronotherapy
The Balance of Giving: Understanding Risks for Living Kidney Donors
Vitamin D in Dialysis is a Dud
Lanreotide rubs the ADPKD lamp but there's no Genie
Water, water everywhere, but how much to drink?
Kidney Transplant & Race and Ethnicity: Things are Getting Better - Or Are They?
Curing Cast Nephropathy by Removing Not-so-light Chains?
IgA Nephropathy: Testing Steroids Again
Dialysis for the Undocumented Immigrant
Could it be that Simple: A Vitamin to Protect the Kidney?
#NephJC on AKI timing: some comparisons
The winners of the #JAMAcup
At every #NephJC chat I find myself delighted with the bits of Twitter wisdom that get funneled through the hashtag. We are going to try to do a better job of rewarding the best of these. Some of these awards will even have prizes. This week we are delighted to announce winners of a great looking JAMA coffee mug, named the JAMAcup in this pre-chat banter:
The winner of the #JAMAcup for the Tuesday night chat is Azra Bihorac (@AzraBihorac) who wrote this gem:
We would also like to give honorable mention (but no mug) to Mike Walsh (@lastwalsh) who was the first to alert us to the negative results for RIPC in other large trials:
The Wednesday chat was great and picking a winner was difficult but we selected this dejavu all over again tweet by Graham Abra (@GrahamAbra):
Honorable mention to Michael Hultström (@mhulstrom) for this:
A hearty thanks to JAMA. We love working with them and appreciate their support of post-publication peer review.